Jena-based Smart­Dye­Liv­ery GmbH attracts new pri­vate investor and suc­cess­fully closes a financ­ing round in the mid-dou­ble-digit mil­lion range

Jena/Erfurt/Austria. Smart­Dye­Liv­ery GmbH has con­vinced an Aus­trian fam­ily office of the poten­tial of its devel­op­ments, thereby gain­ing a strong new part­ner, and suc­cess­fully closed a financ­ing round worth millions.

Smart­Dye­Liv­ery is devel­op­ing a broadly applic­a­ble plat­form tech­nol­ogy based on poly­meric nanocar­ri­ers that can be equipped with a nav­i­ga­tion sys­tem, thereby enabling the tar­geted trans­port of active ingre­di­ents into tar­get cells. Smart­Dye­Liv­ery is cur­rently con­duct­ing a Phase I clin­i­cal trial in healthy vol­un­teers with its first prod­uct SDL-M1.

With the new cap­i­tal, Smart­Dye­Liv­ery plans, as a first step, to move to new premises and to expand its state-of-the-art devel­op­ment capa­bil­i­ties for prod­ucts in its pipeline, as well as to increase the nec­es­sary per­son­nel resources. This is intended to strengthen the company’s posi­tion as a provider of inno­v­a­tive drug deliv­ery sys­tems and estab­lish the basis for sus­tain­able growth.

“This financ­ing round marks a key mile­stone on our growth path,” explains Man­ag­ing Direc­tor Dr. Marc Lehmann. “We greatly appre­ci­ate the new investor’s trust and sup­port. In these chal­leng­ing times, we are gain­ing a part­ner who shares our vision and encour­ages us to achieve our ambi­tious goals,” he says, look­ing pos­i­tively to the tasks ahead.

The Smart­Dye­Liv­ery found­ing team, with Pro­fes­sors Ulrich S. Schu­bert, Anja Träger, and Michael Bauer from Friedrich Schiller Uni­ver­sity Jena and Jena Uni­ver­sity Hos­pi­tal, adds: “Such a suc­cess­ful trans­la­tion of excel­lent aca­d­e­mic research into clin­i­cal tri­als demon­strates the poten­tial inher­ent in trans­form­ing early research find­ings into inde­pen­dent spin-offs.”

“An invest­ment of this mag­ni­tude enables Smart­Dye­Liv­ery to suc­cess­fully tackle the upcom­ing chal­lenges and growth phases. How­ever, it is not only an impor­tant mile­stone for the com­pany but also a strong sig­nal for the entire inno­va­tion ecosys­tem in Thuringia,” empha­sizes Ste­fan Jahn, Senior Invest­ment Man­ager at lead investor bm|t, who has been accom­pa­ny­ing Smart­Dye­Liv­ery since the very beginning.

The new investor expressed con­fi­dence in the level of devel­op­ment achieved to date and in the plat­form technology’s great poten­tial. “With our invest­ment, we aim to actively sup­port SmartDyeLivery’s con­tin­ued growth and its planned expan­sion. Both the tech­no­log­i­cal approach and the goal of help­ing patients for whom no or only insuf­fi­cient treat­ment options cur­rently exist align with our phi­los­o­phy,” said the owner of the fam­ily office.

About SmartDyeLivery:

Smart­Dye­Liv­ery GmbH, based in Jena, is devel­op­ing a uni­ver­sal plat­form tech­nol­ogy based on func­tion­al­ized nanopar­ti­cles that can be used to deliver active ingre­di­ents or other pay­loads specif­i­cally to the desired site of action. The goal is to pro­vide new treat­ment options for dis­eases that are cur­rently untreat­able or dif­fi­cult to treat. The inno­v­a­tive, patent-pro­tected tech­nol­ogy can also be used for diag­nos­tic or ther­a­nos­tic applications.

Fur­ther infor­ma­tion: www.smartdyelivery.com

About bm|t:

bm|t beteili­gungs­man­age­ment thürin­gen, based in Erfurt, is the lead­ing address for ven­ture cap­i­tal invest­ments in Thuringia. bm|t cur­rently man­ages 12 funds with a total vol­ume of around EUR 445 mil­lion, which invest in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of com­pany devel­op­ment — both in the start-up and growth phases or in com­pany suc­ces­sion sit­u­a­tions. Fur­ther infor­ma­tion: https://www.bm‑t.com